$SNGX News

Soligenix Increases Maximum Offering Under Sales Agreement By $2.96M

Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus

SNGX: Continuing to Analyze FLASH2 Data

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Q1 EPS $(0.28), Inline

SNGX: FLASH2 Trial Recommended to Stop for Futility

SNGX Phase 3 Trial Halted on HyBryte

Soligenix shares are trading lower after the company announced that its Phase 3 FLASH2 trial of HyBryte received a recommendation to halt for futility.

Soligenix shares are trading lower after the company announced that its Phase 3 FLASH2 trial of HyBryte received a recommendation to halt for futility.

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Why Is Soligenix Stock Sinking Tuesday?

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

The Data Monitoring Committee Recommends Soligenix To Halt Phase 3 FLASH2 Trial Of HyBryte (Synthetic Hypericin) For Cutaneous T-cell lymphoma For Futility

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results

SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26

Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy